New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - denosumab 60 mg/ml;   - solution for injection - 60 mg/ml - active: denosumab 60 mg/ml   excipient: acetic acid polysorbate 20 sodium hydroxide sorbitol water for injection - the treatment of osteoporosis in postmenopausal women. prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures. treatment to increase bone mass in men with osteoporosis at increased risk of fracture.

Israel - English - Ministry of Health

amgen europe b.v. - denosumab - solution for injection - denosumab 120 mg / 1.7 ml - denosumab - denosumab - prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with multiple myeloma and in adults with bone metastases from solid tumours.treatment of adult and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

amgen biopharmaceuticals malaysia sdn bhd - evolocumab -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

amgen biopharmaceuticals malaysia sdn bhd - evolocumab -

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 10 mcg / 0.4 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 100 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 150 mcg / 0.3 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age.aranesp ® is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 20 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 30 mcg / 0.3 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 40 mcg / 0.4 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age